Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Tarsus Pharmaceuticals Inc
(NQ:
TARS
)
25.53
+0.22 (+0.87%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Tarsus Pharmaceuticals Inc
< Previous
1
2
Next >
Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
August 08, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
July 29, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus to Participate in Upcoming Investor Conferences
May 29, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference
May 09, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) is a Stock Spotlight on 4/15
April 15, 2024
Via
Investor Brand Network
Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements
May 08, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
May 01, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
April 23, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus to Participate at Upcoming Investor Conferences
March 05, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
March 05, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Announces Pricing of $100.0 Million Public Offering
March 01, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Announces Proposed $100.0 Million Public Offering
February 29, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
February 27, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease
February 22, 2024
TP-05 demonstrated tolerability and statistically significant tick mortality, suggesting potential for on-demand Lyme disease prophylaxis
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
February 20, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference
January 31, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) Making Surprising Moves in Monday Session
January 29, 2024
Via
Investor Brand Network
Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites
December 11, 2023
TP-03 demonstrated statistically significant and clinically meaningful improvements across two objective measures of MGD, regardless of BID or TID dosing, and was well tolerated
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) Making Surprising Moves in Friday Session
November 10, 2023
Via
Investor Brand Network
Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements
November 09, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
November 01, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis
September 06, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus to Present at Upcoming Investor Conferences
August 30, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis
August 24, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements
August 10, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock
August 01, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock
July 31, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis
July 25, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) Climbs to New 52-Week High
July 20, 2023
Via
Investor Brand Network
Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis
June 12, 2023
Webcast scheduled for Thursday, June 15 at 8:30am PT
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.